Related Experiment Videos

The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement

Hatice Yildirim1, Lülüfer Tamer, Nehir Sucu

  • 1Department of Biochemistry, Mersin University Faculty of Medicine, Mersin, Turkey.

Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre
|October 7, 2008
PubMed

Insights

Genetic variations in CYP2C9 influence warfarin dosage in heart valve replacement patients. Individuals with specific CYP2C9 genotypes require lower warfarin doses for effective anticoagulation.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Surgery
  • Clinical Chemistry

Background:

  • Warfarin is a critical anticoagulant medication used post-heart valve replacement.
  • CYP2C9 gene polymorphisms are known to affect warfarin metabolism and efficacy.
  • Understanding these genetic variations is crucial for personalized warfarin therapy.

Purpose of the Study:

  • To examine the impact of CYP2C9 gene polymorphisms on warfarin dosage requirements in patients who have undergone heart valve replacement.
  • To correlate specific CYP2C9 alleles with the maintenance dose of warfarin.

Main Methods:

  • Genotyping of CYP2C9*2 and CYP2C9*3 alleles using real-time PCR in 74 heart valve replacement patients.
  • DNA extraction from peripheral blood leukocytes.
  • Analysis of mean weekly warfarin dosage based on identified CYP2C9 genotypes.

Main Results:

  • Patients with CYP2C9*1/*3 and CYP2C9*2/*3 genotypes required significantly lower mean weekly warfarin doses (28.21 mg and 24.47 mg, respectively) compared to wild-type (CYP2C9*1/*1) patients (33.90 mg).
  • This indicates a dose-reduction need for patients carrying variant CYP2C9 alleles.

Conclusions:

  • CYP2C9 gene polymorphisms significantly influence warfarin maintenance dose in heart valve replacement patients.
  • Patients with CYP2C9*1/*3 and CYP2C9*2/*3 genotypes necessitate lower warfarin doses than those with the wild-type genotype.
  • These findings support the application of pharmacogenomic testing for optimizing warfarin therapy in this patient cohort.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...